Biochemical evidence of atherosclerosis progression mediated by increased oxidative stress in apolipoprotein E-deficient spontaneously hyperlipidemic mice exposed to chronic cigarette smoke

Journal of Pharmacological Sciences

Volumn 110, Issue 3, 2009, Pages 354-361

  Kunitomo, Masaru ^a   Yamaguchi, Yu ^a   Kagota, Satomi ^a   Yoshikawa, Noriko ^a   Nakamura, Kazuki ^a   Shinozuka, Kazumasa ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Apolipoprotein E deficient spontaneously hyperlipidemic mice; Atherosclerosis; Cigarette smoking; Oxidative stress; Vitamin E

Indexed keywords

3 NITROTYROSINE; ALPHA TOCOPHEROL; CIGARETTE SMOKE; LOW DENSITY LIPOPROTEIN; NICOTINE; TAR; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 67749142093     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09100FP     Document Type: Article

References (50)

1. Glantz SA, Parmley WW. Passive smoking and heart disease: epidemiology, physiology, and biochemistry. Circulation. 1991; 83:1-12.
2. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association: American Heart Association Task Force on Risk Reduction. Circulation. 1997;96:3243-3247.
3. Howard G, Wagenknecht LE, Burke GL, Szklo M, Tell GS, Eckfeldt J, et al. Cigarette smoking and progression of atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. JAMA. 1998;279:119-124. (Pubitemid 28068301)
4. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002. (Pubitemid 32295654)
5. Zhu BQ, Sun YP, Sievers RE, Isenberg WM, Glantz SA, Parmley WW. Passive smoking increases experimental atherosclerosis in cholesterol-fed rabbits. J Am Coll Cardiol. 1993; 21:225-232.
6. Penn A, Snyder CA. Inhalation of sidestream cigarette smoke accelerates development of arteriosclerotic plaques. Circulation. 1993;90:1820-1825. (Pubitemid 23296929)
7. Iso H, Shimamoto T, Sato S, Koike K, Iida M, Komachi Y. Passive smoking and plasma fibrinogen concentrations. Am J Epidemiol. 1996;144:1151-1154. (Pubitemid 26415105)
8. Stavroulakis GA, Makris TK, Hatzizacharias AN, Tsoukala C, Kyriakidis MK. Passive smoking adversely affects the haemostasis / fibrinolytic parameters in healthy non-smoker offspring of healthy smokers. Thromb Haemost. 2000;84:923-924. (Pubitemid 30946963)
9. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167-2176. (Pubitemid 28057118)
10. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149-2155. (Pubitemid 23326094)
11. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Heavy and light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity: an in vivo and in vitro correlation. J Am Coll Cardiol. 2002;39:1758-1763.
12. Kakafika AI, Mikhailidis DP. Smoking and aortic diseases. Circ J. 2007;71:1173-1180.
13. Miller ER 3rd, Appel LJ, Jiang L, Risby TH. Association between cigarette smoking and lipid peroxidation in a controlled feeding study. Circulation. 1997;96:1097-1101.
14. Frei B, Forte TM, Ames BN, Cross CE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J. 1991;277:133-138.
15. Pryor WA. Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci. 1993;686:12-28.
16. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. N Engl J Med. 1995;332: 1198-1203.
17. Yamaguchi Y, Haginaka J, Morimoto S, Fujioka Y, Kunitomo M. Facilitated nitration and oxidation of LDL in cigarette smokers. Eur J Clin Invest. 2005;35:186-193. (Pubitemid 40343884)
18. Bernhard D, Wang XL. Smoking, oxidative stress and cardiovascular diseases - do anti-oxidative therapies fail? Curr Med Chem. 2007;14:1703-1712.
19. Yamaguchi Y, Nasu F, Harada A, Kunitomo M. Oxidants in the gas phase of cigarette smoke pass through the lung alveolar wall and raise systemic oxidative stress. J Pharmacol Sci. 2007;103: 275-282. (Pubitemid 46465770)
20. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest. 2007;131: 1557-1566.
21. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-1478.
22. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002; 22:1162-1167. (Pubitemid 34764868)
23. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apoE: evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-147. (Pubitemid 24028178)
24. Matsushima Y, Hayashi S, Tachibana M. Spontaneously hyperlipidemic (SHL) mice: Japanese wild mice with apolipoprotein E deficiency. Mamm Genome. 1999;10:352-357. (Pubitemid 29390485)
25. Nagarajan S, Burris RL, Stewart BW, Wilkerson JE, Badger TM. Dietary soy protein isolate ameliorates atherosclerotic lesions in apolipoprotein E-deficient mice potentially by inhibiting monocyte chemoattractant protein-1 expression. J Nutr. 2008;138:332-337. (Pubitemid 351213648)
26. Gairola CG, Drawdy ML, Block AE, Daugherty A. Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E-/-mice. Atherosclerosis. 2001;156:49-55. (Pubitemid 32429594)
27. Tani S, Dimayuga PC, Anazawa T, Chyu KY, Li H, Shah PK, et al. Aberrant antibody responses to oxidized LDL and increased intimal thickening in apoE-/- mice exposed to cigarette smoke. Atherosclerosis. 2004;175:7-14. (Pubitemid 38746904)
28. Catanzaro DF, Zhou Y, Chen R, Yu F, Catanzaro SE, De Lorenzo MS, et al. Potentially reduced exposure cigarettes accelerate atherosclerosis: evidence for the role of nicotine. Cardiovasc Toxicol. 2007;7:192-201. (Pubitemid 47575004)
29. Matsushima Y, Sakurai T, Ohoka A, Ohnuki T, Tada N, Asoh Y, et al. Four strains of spontaneously hyperlipidemic (SHL) mice: phenotypic distinctions determined by genetic backgrounds. J Atheroscler Thromb. 2001;8:71-79.
30. Yamaguchi Y, Kagota S, Kunitomo M, Haginaka J. Evidence of modified lipoprotein in the plasma of Watanabe Heritable Hyperlipidaemic rabbits by anion-exchange high-performance liquid chromatographic assay. Atherosclerosis. 1998;139:323-331. (Pubitemid 28361817)
31. Yamaguchi Y, Kagota S, Haginaka J, Kunitomo M. Participation of peroxynitrite in oxidative modification of LDL by aqueous extracts of cigarette smoke. FEBS Lett. 2002;512:218-222. (Pubitemid 34164482)
32. Kunitomo M, Yamaguchi Y, Matsushima K, Bando Y. Cholesterol metabolism in serum and aorta of inbred mice fed a high-cholesterol diet. Jpn J Pharmacol. 1984;34:153-158. (Pubitemid 14053717)
33. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 1976;15:212-216.
34. Yamaguchi Y, Kitagawa S, Imaizumi N, Kunitomo M, Fujiwara M. Enhancement of aortic cholesterol deposition by dietary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents. J Pharmacol Toxicol Methods. 1993;30:169-175. (Pubitemid 24014390)
35. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol. 2004;55:503-517.
36. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantov R, Levin LF, et al. Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:1960-1968. (Pubitemid 29379929)
37. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002;105:2107-2111.
38. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitriteinduced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991;288: 481-487. (Pubitemid 21909347)
39. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075-2081.
40. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391:393-397. (Pubitemid 28093514)
41. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, et al. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest. 2002;109:1311-1319. (Pubitemid 34546895)
42. Suzuki K, Ito Y, Ochiai J, Aoki K, Wakai K, Tamakoshi A, et al. The relationship between smoking habits and serum levels of 8-OHdG, oxidized LDL antibodies, Mn-SOD and carotenoids in rural Japanese residents. Japan Collaborative Cohort Study Group. J Epidemiol. 2003;13:29-37. (Pubitemid 44137125)
43. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol. 2005;25:279-286.
44. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
45. Adams MR, Golden DL, Anthony MS, Register TC, Williams JK. The inhibitory effect of soy protein isolate on atherosclerosis in mice does not require the presence of LDL receptors or alteration of plasma lipoproteins. J Nutr. 2002;132:43-49.
46. Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest. 2000;106:1501-1510. (Pubitemid 32038588)
47. Steinberg D. LDL oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
48. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844. (Pubitemid 30943820)
49. Lavi S, Prasad A, Yang EH, Mathew V, Simari RD, Rihal CS, et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation. 2007;115:2621-2627. (Pubitemid 46791360)
50. Rudolph TK, Rudolph V, Baldus S. Contribution of myeloperoxidase to smoking-dependent vascular inflammation. Proc Am Thorac Soc. 2008;5:820-823.